Payment overview · 2025
General Payments
$62.10
3 reported records · 3 companies
Healthcare provider profile · identity verified
Bill M Balch, MD
Allopathic & Osteopathic Physicians|Internal Medicine · DENISON, TX · NPI 1548219959
Verified facts
What the public records show
CMS Open Payments records show Bill M Balch, MD received $62.10 in general payments during 2025 across 3 reported records.
Otsuka America Pharmaceutical, Inc. accounted for 38.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 3 associated products.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Prolia by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $24.02 | 38.7% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $22.43 | 36.1% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $15.65 | 25.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $62.10 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $24.02 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $22.43 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $15.65 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 509 | 136 |
| Alprazolam | Alprazolam | 480 | 77 |
| Atorvastatin Calcium | Atorvastatin Calcium | 450 | 128 |
| Gabapentin | Gabapentin | 338 | 83 |
| Pantoprazole Sodium | Pantoprazole Sodium | 338 | 86 |
| Amlodipine Besylate | Amlodipine Besylate | 335 | 94 |
| Furosemide | Furosemide | 330 | 103 |
| Potassium Chloride | Potassium Chloride | 274 | 69 |
| Losartan Potassium | Losartan Potassium | 266 | 71 |
| Metoprolol Succinate | Metoprolol Succinate | 258 | 72 |
| Simvastatin | Simvastatin | 241 | 65 |
| Tamsulosin Hcl | Tamsulosin Hcl | 232 | 65 |
| Omeprazole | Omeprazole | 227 | 63 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 216 | 35 |
| Metformin Hcl | Metformin Hcl | 207 | 59 |
| Clopidogrel | Clopidogrel Bisulfate | 202 | 57 |
| Trazodone Hcl | Trazodone Hcl | 201 | 38 |
| Tramadol Hcl | Tramadol Hcl | 192 | 57 |
| Lisinopril | Lisinopril | 176 | 51 |
| Metoprolol Tartrate | Metoprolol Tartrate | 171 | 46 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 170 | 51 |
| Glimepiride | Glimepiride | 164 | 46 |
| Citalopram Hbr | Citalopram Hydrobromide | 157 | 39 |
| Alendronate Sodium | Alendronate Sodium | 141 | 39 |
| Allopurinol | Allopurinol | 132 | 32 |
| Finasteride | Finasteride | 131 | 43 |
| Azithromycin | Azithromycin | 117 | 90 |
| Hydrochlorothiazide | Hydrochlorothiazide | 117 | 28 |
| Lorazepam | Lorazepam | 115 | 26 |
| Duloxetine Hcl | Duloxetine Hcl | 113 | 26 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 111 | 35 |
| Temazepam | Temazepam | 107 | 16 |
| Montelukast Sodium | Montelukast Sodium | 99 | 29 |
| Donepezil Hcl | Donepezil Hcl | 98 | 27 |
| Methylprednisolone | Methylprednisolone | 96 | 76 |
| Sertraline Hcl | Sertraline Hcl | 95 | 21 |
| Ropinirole Hcl | Ropinirole Hcl | 94 | 21 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 91 | 37 |
| Carvedilol | Carvedilol | 84 | 23 |
| Pregabalin | Pregabalin | 82 | 19 |
| Meloxicam | Meloxicam | 78 | 23 |
| Tizanidine Hcl | Tizanidine Hcl | 75 | 22 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 74 | 34 |
| Mirtazapine | Mirtazapine | 74 | 15 |
| Synthroid | Levothyroxine Sodium | 74 | 16 |
| Clonazepam | Clonazepam | 73 | 12 |
| Acyclovir | Acyclovir | 72 | 19 |
| Doxycycline Hyclate | Doxycycline Hyclate | 72 | 51 |
| Escitalopram Oxalate | Escitalopram Oxalate | 72 | 20 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 69 | 56 |
| Estradiol | Estradiol | 69 | 21 |
| Lovastatin | Lovastatin | 68 | 16 |
| Eliquis | Apixaban | 66 | 14 |
| Ozempic | Semaglutide | 66 | 16 |
| Prednisone | Prednisone | 66 | 22 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 65 | 20 |
| Zolpidem Tartrate | Zolpidem Tartrate | 64 | 17 |
| Bupropion Xl | Bupropion Hcl | 62 | 15 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 62 | 18 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 62 | 18 |
| Dicyclomine Hcl | Dicyclomine Hcl | 61 | 17 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 60 | 18 |
| Pravastatin Sodium | Pravastatin Sodium | 60 | 19 |
| Methocarbamol | Methocarbamol | 59 | 22 |
| Atenolol | Atenolol | 58 | 14 |
| Buspirone Hcl | Buspirone Hcl | 58 | 20 |
| Cefdinir | Cefdinir | 57 | 48 |
| Ezetimibe | Ezetimibe | 57 | 16 |
| Fluoxetine Hcl | Fluoxetine Hcl | 57 | 17 |
| Spironolactone | Spironolactone | 51 | 13 |
| Fluticasone Propionate | Fluticasone Propionate | 49 | 17 |
| Topiramate | Topiramate | 49 | 11 |
| Xarelto | Rivaroxaban | 45 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 44 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 44 | 12 |
| Memantine Hcl | Memantine Hcl | 43 | 11 |
| Primidone | Primidone | 43 | suppressed |
| Cephalexin | Cephalexin | 41 | 28 |
| Fluconazole | Fluconazole | 41 | 24 |
| Promethazine Hcl | Promethazine Hcl | 41 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 40 | suppressed |
| Lidocaine | Lidocaine | 40 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 40 | 26 |
| Baclofen | Baclofen | 39 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 39 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 38 | 15 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 35 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 35 | 14 |
| Glipizide | Glipizide | 34 | suppressed |
| Linzess | Linaclotide | 34 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 34 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 33 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 32 | 12 |
| Sumatriptan Succinate | Sumatriptan Succinate | 31 | suppressed |
| Fenofibrate | Fenofibrate | 30 | suppressed |
| Myrbetriq | Mirabegron | 30 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 30 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 29 | 18 |
| Celecoxib | Celecoxib | 28 | suppressed |
| Mounjaro | Tirzepatide | 28 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 27 | suppressed |
| Diazepam | Diazepam | 27 | suppressed |
| Digoxin | Digoxin | 27 | suppressed |
| Ondansetron Odt | Ondansetron | 27 | 15 |
| Pioglitazone Hcl | Pioglitazone Hcl | 27 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 26 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 26 | suppressed |
| Levofloxacin | Levofloxacin | 25 | 21 |
| Oxybutynin Chloride | Oxybutynin Chloride | 25 | suppressed |
| Famotidine | Famotidine | 24 | suppressed |
| Gemfibrozil | Gemfibrozil | 24 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 24 | suppressed |
| Mupirocin | Mupirocin | 24 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 24 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 23 | 13 |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 23 | suppressed |
| Fentanyl | Fentanyl | 23 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 23 | 13 |
| Nitroglycerin | Nitroglycerin | 23 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 23 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 23 | suppressed |
| Repatha Syringe | Evolocumab | 22 | suppressed |
| Levetiracetam | Levetiracetam | 21 | suppressed |
| Nystatin | Nystatin | 21 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 21 | suppressed |
| Valsartan | Valsartan | 21 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 21 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 20 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 20 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 20 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 19 | suppressed |
| Gemtesa | Vibegron | 19 | suppressed |
| Glyburide | Glyburide | 19 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 19 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 19 | suppressed |
| Latanoprost | Latanoprost | 19 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Dutasteride | Dutasteride | 18 | suppressed |
| Ranolazine Er | Ranolazine | 17 | suppressed |
| Repatha Sureclick | Evolocumab | 17 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 15 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 15 | suppressed |
| Folic Acid | Folic Acid | 15 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 15 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Amoxicillin | Amoxicillin | 14 | 11 |
| Doxazosin Mesylate | Doxazosin Mesylate | 14 | suppressed |
| Januvia | Sitagliptin Phosphate | 14 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 14 | suppressed |
| Prolia | Denosumab | 14 | suppressed |
| Risperidone | Risperidone | 14 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 14 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 13 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 13 | suppressed |
| Lamotrigine | Lamotrigine | 13 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 13 | suppressed |
| Rybelsus | Semaglutide | 13 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 12 | suppressed |
| Phenobarbital | Phenobarbital | 12 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 12 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 12 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Butalb-Acetaminoph-Caff-Codein | Butalbit/Acetamin/Caff/Codeine | 11 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 11 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 11 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 11 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 11 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 11 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $62.10 · 3 records | Otsuka America Pharmaceutical, Inc. | EVENITY, Korlym, REXULTI | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error